Capmatinib: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
use canonicalized SMILES
update links
 
(17 intermediate revisions by 9 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Use dmy dates|date=May 2020}}
{{Use dmy dates|date=September 2022}}
{{Infobox drug
{{Infobox drug
| drug_name =
| INN =
| type = <!-- empty -->
| image = Capmatinib.svg
| image = Capmatinib.svg
| width =
| width =
Line 14: Line 12:
| Drugs.com = {{drugs.com|monograph|capmatinib}}
| Drugs.com = {{drugs.com|monograph|capmatinib}}
| MedlinePlus = a620038
| MedlinePlus = a620038
| licence_CA = <!-- Health Canada may use generic or brand name (generic name preferred) -->
| licence_EU = <!-- EMA uses INN (or special INN_EMA) -->
| DailyMedID = Capmatinib
| DailyMedID = Capmatinib
| licence_US = <!-- FDA may use generic or brand name (generic name preferred) -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment =
| pregnancy_AU_comment =
| pregnancy_category= Not recommended
| pregnancy_category= Not recommended
| dependency_liability =
| addiction_liability =
| routes_of_administration = [[Oral administration|By mouth]]
| routes_of_administration = [[Oral administration|By mouth]]
| class =
| class =
| ATCvet =
| ATC_prefix = L01
| ATC_prefix = L01
| ATC_suffix = EX17
| ATC_suffix = EX17
Line 35: Line 27:
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment =
| legal_BR_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA = Rx-only
| legal_CA_comment = <ref>{{cite web | title=Summary Basis of Decision - Tabrecta | website=Health Canada | date=30 August 2022 | url=https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00602&lang=en | access-date=29 September 2022 | archive-date=29 September 2022 | archive-url=https://web.archive.org/web/20220929050122/https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00602&lang=en | url-status=live }}</ref>
| legal_CA_comment =
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment =
| legal_DE_comment =
Line 45: Line 37:
| legal_US = Rx-only
| legal_US = Rx-only
| legal_US_comment = <ref name="Tabrecta FDA label" />
| legal_US_comment = <ref name="Tabrecta FDA label" />
| legal_EU = Rx-only
| legal_EU_comment = <ref name="Tabrecta EPAR">{{cite web | title=Tabrecta EPAR | website=European Medicines Agency | date=13 April 2022 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/tabrecta | access-date=21 September 2022 | archive-date=22 September 2022 | archive-url=https://web.archive.org/web/20220922033953/https://www.ema.europa.eu/en/medicines/human/EPAR/tabrecta | url-status=live }}</ref>
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment =
| legal_UN_comment =
Line 60: Line 54:


<!-- Identifiers -->
<!-- Identifiers -->
| CAS_number_Ref =
| CAS_number = 1029712-80-8
| CAS_number = 1029712-80-8
| CAS_supplemental =
| CAS_supplemental =
| PubChem = 25145656
| PubChem = 25145656
| IUPHAR_ligand =
| IUPHAR_ligand =
| DrugBank_Ref =
| DrugBank = DB11791
| DrugBank = DB11791
| ChemSpiderID_Ref =
| ChemSpiderID = 25069712
| ChemSpiderID = 25069712
| UNII_Ref =
| UNII = TY34L4F9OZ
| UNII = TY34L4F9OZ
| KEGG_Ref =
| KEGG = D10891
| KEGG = D10891
| KEGG2_Ref =
| KEGG2 = D10696
| KEGG2 = D10696
| ChEBI_Ref =
| ChEBI =
| ChEBI =
| ChEMBL_Ref =
| ChEMBL = 3188267
| ChEMBL = 3188267
| NIAID_ChemDB =
| NIAID_ChemDB =
Line 84: Line 70:


<!-- Chemical and physical data -->
<!-- Chemical and physical data -->
| IUPAC_name = 2-Fluoro-''N''-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-''b''][1,2,4]triazin-2-yl]benzamide
| IUPAC_name =
| C = 23 | H = 17 | F = 1 | N = 6 | O = 1
| C = 23 | H = 17 | F = 1 | N = 6 | O = 1
| SMILES = CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F
| SMILES = CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F
Line 102: Line 88:
}}
}}


'''Capmatinib''', sold under the brand name '''Tabrecta''', is a medication for the treatment of adults with metastatic [[non-small cell lung cancer]] (NSCLC) whose tumors have a mutation that leads to the exon 14 skipping of the ''MET'' gene, which codes for the membrane receptor HGFR, as detected by an FDA-approved test.<ref name="Tabrecta FDA label">{{cite web | title=Tabrecta- capmatinib tablet, film coated | website=DailyMed | date=6 May 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=455892c3-d144-4ba8-9ab4-79cabff9876d | access-date=8 May 2020}}</ref><ref name="FDA PR">{{cite press release | title=FDA Approves First Targeted Therapy to Treat Aggressive Form of Lung Cancer | website=U.S. [[Food and Drug Administration]] (FDA) | date=6 May 2020 | url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-treat-aggressive-form-lung-cancer | access-date=8 May 2020}} {{PD-notice}}</ref><ref name="FDA snapshot" />
'''Capmatinib''', sold under the brand name '''Tabrecta''', is an [[anticancer medication]] used for the treatment of metastatic [[non-small cell lung cancer]] whose tumors have a mutation that leads to the exon 14 skipping of the [[Hepatocyte growth factor receptor|''MET'' gene]], which codes for the membrane receptor HGFR.<ref name="Tabrecta FDA label">{{cite web | title=Tabrecta- capmatinib tablet, film coated | website=DailyMed | date=6 May 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=455892c3-d144-4ba8-9ab4-79cabff9876d | access-date=8 May 2020 | archive-date=8 May 2020 | archive-url=https://web.archive.org/web/20200508233930/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=455892c3-d144-4ba8-9ab4-79cabff9876d | url-status=live }}</ref><ref name="Tabrecta EPAR" /><ref name="FDA PR">{{cite press release | title=FDA Approves First Targeted Therapy to Treat Aggressive Form of Lung Cancer | website=U.S. [[Food and Drug Administration]] (FDA) | date=6 May 2020 | url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-treat-aggressive-form-lung-cancer | access-date=8 May 2020 | archive-date=7 May 2020 | archive-url=https://web.archive.org/web/20200507014844/https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-treat-aggressive-form-lung-cancer | url-status=live }} {{PD-notice}}</ref><ref name="FDA snapshot" />


The most common adverse reactions are peripheral [[edema]], nausea, fatigue, vomiting, [[dyspnea]], and decreased appetite.<ref name="Tabrecta FDA label" /><ref name="FDA capmatinib" /><ref name="FDA PR" />
The most common adverse reactions are peripheral [[edema]], nausea, fatigue, vomiting, [[dyspnea]], and decreased appetite.<ref name="Tabrecta FDA label" /><ref name="FDA capmatinib" /><ref name="FDA PR" />


Non-small cell lung cancer (NSCLC) is a disease in which malignant cancer cells form in the tissues of the lung.<ref name="FDA PR" /> It is the most common type of lung cancer with up to 90% of all lung carcinomas falling into the non-small cell category.<ref name="FDA PR" /> NSCLC occurs when healthy cells become abnormal and grow rapidly.<ref name="FDA PR" /> One danger of this form of cancer is that there's a high likelihood that the cancer cells will spread from the lungs to other organs and body parts.<ref name="FDA PR" /> Cancer metastasis consists of a sequential series of events, and MET exon 14 skipping is recognized as a critical event for metastasis of carcinomas.<ref name="FDA PR" /> Mutations leading to MET exon 14 skipping are found in 3-4% of people with lung cancer.<ref name="FDA PR" />
Non-small cell lung cancer is a disease in which malignant cancer cells form in the tissues of the lung.<ref name="FDA PR" /> It is the most common type of lung cancer with up to 90% of all lung carcinomas falling into the non-small cell category.<ref name="FDA PR" /> Non-small cell lung cancer occurs when healthy cells become abnormal and grow rapidly.<ref name="FDA PR" /> One danger of this form of cancer is that there's a high likelihood that the cancer cells will spread from the lungs to other organs and body parts.<ref name="FDA PR" /> Cancer metastasis consists of a sequential series of events, and MET exon 14 skipping is recognized as a critical event for metastasis of carcinomas.<ref name="FDA PR" /> Mutations leading to MET exon 14 skipping are found in 3-4% of people with lung cancer.<ref name="FDA PR" />

Capmatinib was approved for medical use in the United States in May 2020.<ref>{{cite web | title=FDA grants accelerated approval to capmatinib for metastatic non-small | website=U.S. Food and Drug Administration | date=11 June 2021 | url=https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-capmatinib-metastatic-non-small-cell-lung-cancer | access-date=26 January 2023}}</ref><ref>{{cite web | title=FDA approves capmatinib for metastatic non-small cell lung cancer | website=U.S. Food and Drug Administration | date=10 August 2022 | url=https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capmatinib-metastatic-non-small-cell-lung-cancer | access-date=26 January 2023}}</ref>


Capmatinib is the first therapy approved by the US [[Food and Drug Administration]] (FDA) to treat non-small cell lung cancer with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping).<ref name="FDA PR" />
Capmatinib is the first therapy approved by the US [[Food and Drug Administration]] (FDA) to treat non-small cell lung cancer with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping).<ref name="FDA PR" />


== Medical uses ==
== Medical uses ==
Capmatinib is a kinase inhibitor indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.<ref name="Tabrecta FDA label" /><ref name="FDA capmatinib" />
Capmatinib is a kinase inhibitor indicated for the treatment of adults with metastatic non-small cell lung cancer whose tumors have a mutation that leads to [[Hepatocyte growth factor receptor|''MET'']] exon 14 skipping.<ref name="Tabrecta FDA label" /><ref name="FDA capmatinib" /><ref name="Tabrecta EPAR" />


== Adverse effects ==
== Adverse effects ==
Line 119: Line 107:


==Pharmacology==
==Pharmacology==
The substance inhibits [[c-Met]],<ref>{{cite journal | vauthors = Shaker ME, Shaaban AA, El-Shafey MM, El-Mesery ME | title = The selective c-Met inhibitor capmatinib offsets cisplatin-nephrotoxicity and doxorubicin-cardiotoxicity and improves their anticancer efficacies | journal = Toxicology and Applied Pharmacology | volume = 398 | pages = 115018 | date = April 2020 | pmid = 32333917 | doi = 10.1016/j.taap.2020.115018 }}</ref><ref>{{cite journal | vauthors = Qin S, Chan SL, Sukeepaisarnjaroen W, Han G, Choo SP, Sriuranpong V, Pan H, Yau T, Guo Y, Chen M, Ren Z, Xu J, Yen CJ, Lin ZZ, Manenti L, Gu Y, Sun Y, Tiedt R, Hao L, Song W, Tanwandee T | display-authors = 6 | title = A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma | journal = Therapeutic Advances in Medical Oncology | volume = 11 | pages = 1758835919889001 | year = 2019 | pmid = 31853265 | pmc = 6906348 | doi = 10.1177/1758835919889001 }}</ref> a [[tyrosine kinase]] that plays a role in embryonic development, [[organogenesis]] and wound healing, but also in the development of cancer.
The drug inhibits [[c-Met]],<ref>{{cite journal | vauthors = Shaker ME, Shaaban AA, El-Shafey MM, El-Mesery ME | title = The selective c-Met inhibitor capmatinib offsets cisplatin-nephrotoxicity and doxorubicin-cardiotoxicity and improves their anticancer efficacies | journal = Toxicology and Applied Pharmacology | volume = 398 | pages = 115018 | date = April 2020 | pmid = 32333917 | doi = 10.1016/j.taap.2020.115018 | s2cid = 216145815 }}</ref><ref>{{cite journal | vauthors = Qin S, Chan SL, Sukeepaisarnjaroen W, Han G, Choo SP, Sriuranpong V, Pan H, Yau T, Guo Y, Chen M, Ren Z, Xu J, Yen CJ, Lin ZZ, Manenti L, Gu Y, Sun Y, Tiedt R, Hao L, Song W, Tanwandee T | display-authors = 6 | title = A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma | journal = Therapeutic Advances in Medical Oncology | volume = 11 | pages = 1758835919889001 | year = 2019 | pmid = 31853265 | pmc = 6906348 | doi = 10.1177/1758835919889001 }}</ref> a [[tyrosine kinase]] that plays a role in embryonic development, [[organogenesis]] and wound healing, but also in the development of cancer.


== History ==
== History ==
Capmatinib was approved for medical use in the United States in May 2020, along with the FoundationOne CDx assay as a companion diagnostic for capmatinib.<ref name="FDA capmatinib">{{cite web | title=FDA grants accelerated approval to capmatinib for metastatic non-small | website=U.S. [[Food and Drug Administration]] (FDA) | date=6 May 2020 | url=https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-capmatinib-metastatic-non-small-cell-lung-cancer | access-date=6 May 2020}} {{PD-notice}}</ref><ref>{{cite web | title=Tabrecta: FDA-Approved Drugs | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213591 | access-date=6 May 2020}}</ref>
Capmatinib was approved for medical use in the United States in May 2020, along with the FoundationOne CDx assay as a companion diagnostic for capmatinib.<ref name="FDA capmatinib">{{cite web | title=FDA grants accelerated approval to capmatinib for metastatic non-small | website=U.S. [[Food and Drug Administration]] (FDA) | date=6 May 2020 | url=https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-capmatinib-metastatic-non-small-cell-lung-cancer | access-date=6 May 2020 | archive-date=7 May 2020 | archive-url=https://web.archive.org/web/20200507011522/https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-capmatinib-metastatic-non-small-cell-lung-cancer | url-status=live }} {{PD-notice}}</ref><ref>{{cite web | title=Tabrecta: FDA-Approved Drugs | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213591 | access-date=6 May 2020 | archive-date=6 May 2020 | archive-url=https://web.archive.org/web/20200506223716/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213591 | url-status=live }}</ref>


Efficacy was demonstrated in the GEOMETRY mono-1 trial (NCT02414139), a multicenter, non-randomized, open-label, multicohort study enrolling 334 participants with metastatic NSCLC with confirmed MET exon 14 skipping.<ref name="FDA snapshot">{{cite web | title=Drug Trials Snapshots: Tabrecta | website=U.S. [[Food and Drug Administration]] (FDA) | date=6 May 2020 | url=https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tabrecta | access-date=21 May 2020}} {{PD-notice}}</ref><ref name="FDA capmatinib" /> Some participants were previously treated for their cancer and some were not (treatment-naïve).<ref name="FDA snapshot" /> Participants received capmatinib 400&nbsp;mg orally twice daily until disease progression or unacceptable toxicity.<ref name="FDA capmatinib" /><ref name="FDA PR" /> The efficacy was based on results from 97 of the participants.<ref name="FDA snapshot" /> The trial was conducted at 92 sites in the United States, Austria, Belgium, France, Germany, Israel, Italy, Japan, Korea, Lebanon, Mexico, Netherlands, Norway, Russia, Singapore, Sweden, Switzerland, Spain, Taiwan and the UK.<ref name="FDA snapshot" />
Efficacy was demonstrated in the GEOMETRY mono-1 trial (NCT02414139), a multicenter, non-randomized, open-label, multicohort study enrolling 334 participants with metastatic non-small cell lung cancer with confirmed MET exon 14 skipping.<ref name="FDA snapshot">{{cite web | title=Drug Trials Snapshots: Tabrecta | website=U.S. [[Food and Drug Administration]] (FDA) | date=6 May 2020 | url=https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tabrecta | access-date=21 May 2020 | archive-date=8 August 2020 | archive-url=https://web.archive.org/web/20200808141315/https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tabrecta | url-status=live }} {{PD-notice}}</ref><ref name="FDA capmatinib" /> Some participants were previously treated for their cancer and some were not (treatment-naïve).<ref name="FDA snapshot" /> Participants received capmatinib 400&nbsp;mg orally twice daily until disease progression or unacceptable toxicity.<ref name="FDA capmatinib" /><ref name="FDA PR" /> The efficacy was based on results from 97 of the participants.<ref name="FDA snapshot" /> The trial was conducted at 92 sites in the United States, Austria, Belgium, France, Germany, Israel, Italy, Japan, Korea, Lebanon, Mexico, Netherlands, Norway, Russia, Singapore, Sweden, Switzerland, Spain, Taiwan and the UK.<ref name="FDA snapshot" />


The major efficacy outcome measure was overall response rate (ORR), which reflects the percentage of participants that had a certain amount of tumor shrinkage.<ref name="FDA PR" /> An additional efficacy outcome measure was duration of response (DOR).<ref name="FDA PR" /> The efficacy population included 28 participants who had never undergone treatment for NSCLC and 69 previously treated participants.<ref name="FDA PR" /> The ORR for the 28 participants was 68%, with 4% having a complete response and 64% having a partial response.<ref name="FDA PR" /> The ORR for the 69 participants was 41%, with all having a partial response.<ref name="FDA PR" /> Of the responding participants who had never undergone treatment for NSCLC, 47% had a duration of response lasting 12 months or longer compared to 32.1% of the responding participants who had been previously treated.<ref name="FDA PR" />
The major efficacy outcome measure was overall response rate (ORR), which reflects the percentage of participants that had a certain amount of tumor shrinkage.<ref name="FDA PR" /> An additional efficacy outcome measure was duration of response (DOR).<ref name="FDA PR" /> The efficacy population included 28 participants who had never undergone treatment for non-small cell lung cancer and 69 previously treated participants.<ref name="FDA PR" /> The ORR for the 28 participants was 68%, with 4% having a complete response and 64% having a partial response.<ref name="FDA PR" /> The ORR for the 69 participants was 41%, with all having a partial response.<ref name="FDA PR" /> Of the responding participants who had never undergone treatment for non-small cell lung cancer, 47% had a duration of response lasting 12 months or longer compared to 32.1% of the responding participants who had been previously treated.<ref name="FDA PR" />


The US [[Food and Drug Administration]] (FDA) processed the application under the [[Accelerated approval (FDA)|accelerated approval program]] and granted the application for capmatinib [[priority review]], [[orphan drug]], and [[breakthrough therapy]] designations<ref name="FDA capmatinib" /><ref name="FDA PR" /> and granted the approval of Tabrecta to Novartis Pharmaceuticals Corporation.<ref name="FDA capmatinib" /><ref name="FDA PR" />
The US [[Food and Drug Administration]] (FDA) processed the application under the [[Accelerated approval (FDA)|accelerated approval program]] and granted the application for capmatinib [[priority review]], [[orphan drug]], and [[breakthrough therapy]] designations<ref name="FDA capmatinib" /><ref name="FDA PR" /> and granted the approval of Tabrecta to Novartis Pharmaceuticals Corporation.<ref name="FDA capmatinib" /><ref name="FDA PR" />

== Society and culture ==
=== Legal status ===
On 22 April 2022, the [[Committee for Medicinal Products for Human Use]] (CHMP) of the [[European Medicines Agency]] (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Tabrecta, intended for treatment of patients with advanced non-small cell lung cancer harboring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping.<ref name="Tabrecta: Pending EC decision" /> The applicant for this medicinal product is Novartis Europharm Limited.<ref name="Tabrecta: Pending EC decision">{{cite web | title=Tabrecta: Pending EC decision | website=[[European Medicines Agency]] (EMA) | date=22 April 2022 | url=https://www.ema.europa.eu/en/medicines/human/summaries-opinion/tabrecta | access-date=22 April 2022 | archive-date=22 April 2022 | archive-url=https://web.archive.org/web/20220422152125/https://www.ema.europa.eu/en/medicines/human/summaries-opinion/tabrecta | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref> Capmatinib was approved for medical use in the European Union in September 2022.<ref name="Tabrecta EPAR" /><ref>{{cite web | title=Tabrecta Product information | website=Union Register of medicinal products | url=https://ec.europa.eu/health/documents/community-register/html/h1650.htm | access-date=3 March 2023}}</ref>


== References ==
== References ==
Line 134: Line 126:


== External links ==
== External links ==
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/capmatinib | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Capmatinib }}
* {{cite web | title=Capmatinib hydrochloride | publisher=National Cancer Institute | work=NCI Drug Dictionary | url=https://www.cancer.gov/publications/dictionaries/cancer-drug/def/666907 }}
* {{cite web | title=Capmatinib hydrochloride | publisher=National Cancer Institute | work=NCI Drug Dictionary | url=https://www.cancer.gov/publications/dictionaries/cancer-drug/def/666907 }}
* {{cite web | title=Capmatinib hydrochloride | publisher=National Cancer Institute | url=https://www.cancer.gov/about-cancer/treatment/drugs/capmatinibhydrochloride }}
* {{cite web | title=Capmatinib hydrochloride | publisher=National Cancer Institute | url=https://www.cancer.gov/about-cancer/treatment/drugs/capmatinibhydrochloride }}
Line 144: Line 135:


[[Category:Antineoplastic drugs]]
[[Category:Antineoplastic drugs]]
[[Category:Breakthrough therapy]]
[[Category:Orphan drugs]]
[[Category:Orphan drugs]]
[[Category:Receptor tyrosine kinase inhibitors]]
[[Category:Receptor tyrosine kinase inhibitors]]

Latest revision as of 23:58, 14 March 2024

Capmatinib
Clinical data
Trade namesTabrecta
Other namesINC280
AHFS/Drugs.comMonograph
MedlinePlusa620038
License data
Pregnancy
category
  • Not recommended
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
  • 2-Fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.246.414 Edit this at Wikidata
Chemical and physical data
FormulaC23H17FN6O
Molar mass412.428 g·mol−1
3D model (JSmol)
  • CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F
  • InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)
  • Key:LIOLIMKSCNQPLV-UHFFFAOYSA-N

Capmatinib, sold under the brand name Tabrecta, is an anticancer medication used for the treatment of metastatic non-small cell lung cancer whose tumors have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR.[2][3][4][5]

The most common adverse reactions are peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite.[2][6][4]

Non-small cell lung cancer is a disease in which malignant cancer cells form in the tissues of the lung.[4] It is the most common type of lung cancer with up to 90% of all lung carcinomas falling into the non-small cell category.[4] Non-small cell lung cancer occurs when healthy cells become abnormal and grow rapidly.[4] One danger of this form of cancer is that there's a high likelihood that the cancer cells will spread from the lungs to other organs and body parts.[4] Cancer metastasis consists of a sequential series of events, and MET exon 14 skipping is recognized as a critical event for metastasis of carcinomas.[4] Mutations leading to MET exon 14 skipping are found in 3-4% of people with lung cancer.[4]

Capmatinib was approved for medical use in the United States in May 2020.[7][8]

Capmatinib is the first therapy approved by the US Food and Drug Administration (FDA) to treat non-small cell lung cancer with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping).[4]

Medical uses[edit]

Capmatinib is a kinase inhibitor indicated for the treatment of adults with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping.[2][6][3]

Adverse effects[edit]

Capmatinib can cause interstitial lung disease (a group of lung conditions that causes scarring of lung tissues), pneumonitis (inflammation of the lung tissue), hepatotoxicity (damage to liver cells), photosensitivity, and embryo-fetal toxicity.[6] Based on a clear positive signal for phototoxicity in early laboratory studies in cells, people may be more sensitive to sunlight and should be advised to take precautions to cover their skin, use sunscreen, and not tan while taking capmatinib.[6][4]

Capmatinib may cause harm to a developing fetus or newborn baby.[2][4]

Pharmacology[edit]

The drug inhibits c-Met,[9][10] a tyrosine kinase that plays a role in embryonic development, organogenesis and wound healing, but also in the development of cancer.

History[edit]

Capmatinib was approved for medical use in the United States in May 2020, along with the FoundationOne CDx assay as a companion diagnostic for capmatinib.[6][11]

Efficacy was demonstrated in the GEOMETRY mono-1 trial (NCT02414139), a multicenter, non-randomized, open-label, multicohort study enrolling 334 participants with metastatic non-small cell lung cancer with confirmed MET exon 14 skipping.[5][6] Some participants were previously treated for their cancer and some were not (treatment-naïve).[5] Participants received capmatinib 400 mg orally twice daily until disease progression or unacceptable toxicity.[6][4] The efficacy was based on results from 97 of the participants.[5] The trial was conducted at 92 sites in the United States, Austria, Belgium, France, Germany, Israel, Italy, Japan, Korea, Lebanon, Mexico, Netherlands, Norway, Russia, Singapore, Sweden, Switzerland, Spain, Taiwan and the UK.[5]

The major efficacy outcome measure was overall response rate (ORR), which reflects the percentage of participants that had a certain amount of tumor shrinkage.[4] An additional efficacy outcome measure was duration of response (DOR).[4] The efficacy population included 28 participants who had never undergone treatment for non-small cell lung cancer and 69 previously treated participants.[4] The ORR for the 28 participants was 68%, with 4% having a complete response and 64% having a partial response.[4] The ORR for the 69 participants was 41%, with all having a partial response.[4] Of the responding participants who had never undergone treatment for non-small cell lung cancer, 47% had a duration of response lasting 12 months or longer compared to 32.1% of the responding participants who had been previously treated.[4]

The US Food and Drug Administration (FDA) processed the application under the accelerated approval program and granted the application for capmatinib priority review, orphan drug, and breakthrough therapy designations[6][4] and granted the approval of Tabrecta to Novartis Pharmaceuticals Corporation.[6][4]

Society and culture[edit]

Legal status[edit]

On 22 April 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Tabrecta, intended for treatment of patients with advanced non-small cell lung cancer harboring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping.[12] The applicant for this medicinal product is Novartis Europharm Limited.[12] Capmatinib was approved for medical use in the European Union in September 2022.[3][13]

References[edit]

  1. ^ "Summary Basis of Decision - Tabrecta". Health Canada. 30 August 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.
  2. ^ a b c d e "Tabrecta- capmatinib tablet, film coated". DailyMed. 6 May 2020. Archived from the original on 8 May 2020. Retrieved 8 May 2020.
  3. ^ a b c d "Tabrecta EPAR". European Medicines Agency. 13 April 2022. Archived from the original on 22 September 2022. Retrieved 21 September 2022.
  4. ^ a b c d e f g h i j k l m n o p q r s t "FDA Approves First Targeted Therapy to Treat Aggressive Form of Lung Cancer". U.S. Food and Drug Administration (FDA) (Press release). 6 May 2020. Archived from the original on 7 May 2020. Retrieved 8 May 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  5. ^ a b c d e "Drug Trials Snapshots: Tabrecta". U.S. Food and Drug Administration (FDA). 6 May 2020. Archived from the original on 8 August 2020. Retrieved 21 May 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  6. ^ a b c d e f g h i "FDA grants accelerated approval to capmatinib for metastatic non-small". U.S. Food and Drug Administration (FDA). 6 May 2020. Archived from the original on 7 May 2020. Retrieved 6 May 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  7. ^ "FDA grants accelerated approval to capmatinib for metastatic non-small". U.S. Food and Drug Administration. 11 June 2021. Retrieved 26 January 2023.
  8. ^ "FDA approves capmatinib for metastatic non-small cell lung cancer". U.S. Food and Drug Administration. 10 August 2022. Retrieved 26 January 2023.
  9. ^ Shaker ME, Shaaban AA, El-Shafey MM, El-Mesery ME (April 2020). "The selective c-Met inhibitor capmatinib offsets cisplatin-nephrotoxicity and doxorubicin-cardiotoxicity and improves their anticancer efficacies". Toxicology and Applied Pharmacology. 398: 115018. doi:10.1016/j.taap.2020.115018. PMID 32333917. S2CID 216145815.
  10. ^ Qin S, Chan SL, Sukeepaisarnjaroen W, Han G, Choo SP, Sriuranpong V, et al. (2019). "A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma". Therapeutic Advances in Medical Oncology. 11: 1758835919889001. doi:10.1177/1758835919889001. PMC 6906348. PMID 31853265.
  11. ^ "Tabrecta: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 6 May 2020. Retrieved 6 May 2020.
  12. ^ a b "Tabrecta: Pending EC decision". European Medicines Agency (EMA). 22 April 2022. Archived from the original on 22 April 2022. Retrieved 22 April 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  13. ^ "Tabrecta Product information". Union Register of medicinal products. Retrieved 3 March 2023.

External links[edit]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Capmatinib&oldid=1213760248"